Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMN37M6)

Drug Name
LY3437943 Drug Info
Synonyms retatrutide
Indication
Disease Entry ICD 11 Status REF
Obesity 5B81 Phase 2 [1]
Type 2 diabetes 5A11 Phase 2 [2]
Cross-matching ID
PubChem CID
171390338
TTD Drug ID
DMN37M6

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Gastric inhibitory polypeptide receptor (GIPR) TTYMKBE GIPR_HUMAN Agonist [3]
Glucagon receptor (GCGR) TT9O6WS GLR_HUMAN Agonist [3]
Glucagon-like peptide 1 receptor (GLP1R) TTVIMDE GLP1R_HUMAN Agonist [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Gastric inhibitory polypeptide receptor (GIPR) DTT GIPR 3.511 2.907 1.585 1
Glucagon-like peptide 1 receptor (GLP1R) DTT GLP1R 2 2.848 3.472 2.963
Glucagon receptor (GCGR) DTT GCGR 4.695 1.926 1.322 3.797
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 05 Endocrine, nutritional or metabolic disease
Disease Class ICD-11: 5A11 Type 2 diabetes mellitus
The Studied Tissue Liver tissue
The Studied Disease Type 2 diabetes [ICD-11:5A11]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Gastric inhibitory polypeptide receptor (GIPR) DTT GIPR 6.53E-02 -0.19 -1.27
Glucagon-like peptide 1 receptor (GLP1R) DTT GLP1R 1.25E-01 0.17 1.26
Glucagon receptor (GCGR) DTT GCGR 7.24E-02 -0.52 -0.92
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04881760) A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT04867785) A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes. U.S.National Institutes of Health.
3 LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022 Sep 6;34(9):1234-1247.e9.